189 related articles for article (PubMed ID: 17679818)
1. Atherogenic dyslipidemia in the cardiometabolic syndrome.
Govindarajan G; Chowdhury N; Flaker G
J Cardiometab Syndr; 2006; 1(2):153-5. PubMed ID: 17679818
[No Abstract] [Full Text] [Related]
2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
3. [How to treat dyslipidemia in patients with metabolic syndrome].
Soška V
Vnitr Lek; 2015; 61(7-8):721-4. PubMed ID: 26375703
[TBL] [Abstract][Full Text] [Related]
4. Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges.
Virani SS
Tex Heart Inst J; 2011; 38(2):160-2. PubMed ID: 21494527
[No Abstract] [Full Text] [Related]
5. Atherogenic dyslipidemia.
Hayden MR
J Cardiometab Syndr; 2006; 1(3):166-7. PubMed ID: 17679821
[No Abstract] [Full Text] [Related]
6. Dyslipidemia in the metabolic syndrome in children.
Gidding SS
J Cardiometab Syndr; 2006; 1(4):282-5. PubMed ID: 17679808
[TBL] [Abstract][Full Text] [Related]
7. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
[TBL] [Abstract][Full Text] [Related]
8. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives.
Chapman MJ
Atherosclerosis; 2003 Nov; 171(1):1-13. PubMed ID: 14642400
[TBL] [Abstract][Full Text] [Related]
9. Atherogenic dyslipidemia in patients with established coronary artery disease.
Lahoz C; Mostaza JM; Tranche S; Martin-Jadraque R; Mantilla MT; López-Rodriguez I; Monteiro B; Sanchez-Zamorano MA; Taboada M
Nutr Metab Cardiovasc Dis; 2012 Feb; 22(2):103-8. PubMed ID: 20675108
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease.
Arca M; Montali A; Valiante S; Campagna F; Pigna G; Paoletti V; Antonini R; Barillà F; Tanzilli G; Vestri A; Gaudio C
Am J Cardiol; 2007 Nov; 100(10):1511-6. PubMed ID: 17996510
[TBL] [Abstract][Full Text] [Related]
11. Dyslipidaemia, hypercoagulability and the metabolic syndrome.
Kakafika AI; Liberopoulos EN; Karagiannis A; Athyros VG; Mikhailidis DP
Curr Vasc Pharmacol; 2006 Jul; 4(3):175-83. PubMed ID: 16842135
[TBL] [Abstract][Full Text] [Related]
12. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
Ferdinand KC
J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
[TBL] [Abstract][Full Text] [Related]
13. Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction.
Basile J; Houston M; Ferrario CM
J Cardiometab Syndr; 2006; 1(5):358-61. PubMed ID: 17679795
[No Abstract] [Full Text] [Related]
14. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
15. Triglycerides and low HDL cholesterol predict coronary heart disease risk in patients with stable angina.
Caselli C; De Caterina R; Smit JM; Campolo J; El Mahdiui M; Ragusa R; Clemente A; Sampietro T; Clerico A; Liga R; Pelosi G; Rocchiccioli S; Parodi O; Scholte A; Knuuti J; Neglia D;
Sci Rep; 2021 Oct; 11(1):20714. PubMed ID: 34671067
[TBL] [Abstract][Full Text] [Related]
16. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
17. What is the best choice for combination therapy in the management of dyslipidemia of metabolic syndrome?
Turhan H; Yetkin E
Cardiology; 2006; 105(3):139-40; author reply 141. PubMed ID: 16449809
[No Abstract] [Full Text] [Related]
18. Lipids and Cerebrovascular Disease: Research and Practice.
Yaghi S; Elkind MS
Stroke; 2015 Nov; 46(11):3322-8. PubMed ID: 26451029
[No Abstract] [Full Text] [Related]
19. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
[TBL] [Abstract][Full Text] [Related]
20. Attainment of lipid goals and long-term mortality after coronary-artery bypass surgery.
Zafrir B; Saliba W; Jaffe R; Sliman H; Flugelman MY; Sharoni E
Eur J Prev Cardiol; 2019 Mar; 26(4):401-408. PubMed ID: 30426772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
